Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
studies
mNSCLC - L1 - TMB>10Mb, nivolumab plus ipilimumab vs. pemetrexed plus platin, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias progression or deaths (PFS)detailed results CheckMate 227 (NI vs C ; TMB >10 Mb), 2018 0.58 [0.41; 0.82]
0.58 [0.41 ; 0.82 ] CheckMate 227 (NI vs C ; TMB >10 Mb), 2018 1 0% 299 NA not evaluable objective responses (ORR)detailed results CheckMate 227 (NI vs C ; TMB >10 Mb), 2018 2.26 [1.39; 3.66]
2.26 [1.39 ; 3.66 ] CheckMate 227 (NI vs C ; TMB >10 Mb), 2018 1 0% 299 NA not evaluable STRAE (any grade)detailed results CheckMate 227 (NI vs C ; TMB >10 Mb), 2018 2.67 [1.51; 4.74]
2.67 [1.51 ; 4.74 ] CheckMate 227 (NI vs C ; TMB >10 Mb), 2018 1 0% 294 NA not evaluable STRAE (grade 3-4)detailed results CheckMate 227 (NI vs C ; TMB >10 Mb), 2018 2.19 [1.14; 4.20]
2.19 [1.14 ; 4.20 ] CheckMate 227 (NI vs C ; TMB >10 Mb), 2018 1 0% 294 NA not evaluable TRAE (any grade)detailed results CheckMate 227 (NI vs C ; TMB >10 Mb), 2018 1.28 [0.71; 2.30]
1.28 [0.71 ; 2.30 ] CheckMate 227 (NI vs C ; TMB >10 Mb), 2018 1 0% 294 NA not evaluable TRAE (grade 3-4)detailed results CheckMate 227 (NI vs C ; TMB >10 Mb), 2018 1.02 [0.64; 1.65]
1.02 [0.64 ; 1.65 ] CheckMate 227 (NI vs C ; TMB >10 Mb), 2018 1 0% 294 NA not evaluable TRAE leading to discontinuation (any grade)detailed results CheckMate 227 (NI vs C ; TMB >10 Mb), 2018 3.49 [1.78; 6.83]
3.49 [1.78 ; 6.83 ] CheckMate 227 (NI vs C ; TMB >10 Mb), 2018 1 0% 294 NA not evaluable TRAE leading to discontinuation (grade 3-4)detailed results CheckMate 227 (NI vs C ; TMB >10 Mb), 2018 2.90 [1.32; 6.37]
2.90 [1.32 ; 6.37 ] CheckMate 227 (NI vs C ; TMB >10 Mb), 2018 1 0% 294 NA not evaluable Anaemia TRAE (grade 3-4)detailed results CheckMate 227 (NI vs C ; TMB >10 Mb), 2018 0.26 [0.07; 0.92]
0.26 [0.07 ; 0.92 ] CheckMate 227 (NI vs C ; TMB >10 Mb), 2018 1 0% 294 NA not evaluable Asthenia TRAE (grade 3-4)detailed results CheckMate 227 (NI vs C ; TMB >10 Mb), 2018 1.18 [0.23; 5.95]
1.18 [0.23 ; 5.95 ] CheckMate 227 (NI vs C ; TMB >10 Mb), 2018 1 0% 294 NA not evaluable Constipation TRAE (grade 3-4)detailed results CheckMate 227 (NI vs C ; TMB >10 Mb), 2018 0.59 [0.02; 17.65]
0.59 [0.02 ; 17.65 ] CheckMate 227 (NI vs C ; TMB >10 Mb), 2018 1 0% 294 NA not evaluable Decreased appetite TRAE (grade 3-4)detailed results CheckMate 227 (NI vs C ; TMB >10 Mb), 2018 0.29 [0.03; 2.62]
0.29 [0.03 ; 2.62 ] CheckMate 227 (NI vs C ; TMB >10 Mb), 2018 1 0% 294 NA not evaluable Diarrhoea TRAE (grade 3-4)detailed results CheckMate 227 (NI vs C ; TMB >10 Mb), 2018 1.78 [0.29; 10.84]
1.78 [0.29 ; 10.84 ] CheckMate 227 (NI vs C ; TMB >10 Mb), 2018 1 0% 294 NA not evaluable Fatigue TRAE (grade 3-4)detailed results CheckMate 227 (NI vs C ; TMB >10 Mb), 2018 0.29 [0.03; 2.62]
0.29 [0.03 ; 2.62 ] CheckMate 227 (NI vs C ; TMB >10 Mb), 2018 1 0% 294 NA not evaluable Hypothyroidism TRAE (grade 3-4)detailed results CheckMate 227 (NI vs C ; TMB >10 Mb), 2018 1.18 [0.02; 59.79]
1.18 [0.02 ; 59.79 ] CheckMate 227 (NI vs C ; TMB >10 Mb), 2018 1 0% 294 NA not evaluable Nausea TRAE (grade 3-4)detailed results CheckMate 227 (NI vs C ; TMB >10 Mb), 2018 1.18 [0.16; 8.49]
1.18 [0.16 ; 8.49 ] CheckMate 227 (NI vs C ; TMB >10 Mb), 2018 1 0% 294 NA not evaluable Neutropenia TRAE (grade 3-4)detailed results CheckMate 227 (NI vs C ; TMB >10 Mb), 2018 0.03 [0.00; 0.46]
0.03 [0.00 ; 0.46 ] CheckMate 227 (NI vs C ; TMB >10 Mb), 2018 1 0% 294 NA not evaluable Pruritus TRAE (grade 3-4)detailed results CheckMate 227 (NI vs C ; TMB >10 Mb), 2018 4.77 [0.21; 106.62]
4.77 [0.21 ; 106.62 ] CheckMate 227 (NI vs C ; TMB >10 Mb), 2018 1 0% 294 NA not evaluable Rash TRAE (grade 3-4)detailed results CheckMate 227 (NI vs C ; TMB >10 Mb), 2018 7.20 [0.36; 145.12]
7.20 [0.36 ; 145.12 ] CheckMate 227 (NI vs C ; TMB >10 Mb), 2018 1 0% 294 NA not evaluable Vomiting TRAE (grade 3-4)detailed results CheckMate 227 (NI vs C ; TMB >10 Mb), 2018 0.19 [0.02; 1.60]
0.19 [0.02 ; 1.60 ] CheckMate 227 (NI vs C ; TMB >10 Mb), 2018 1 0% 294 NA not evaluable 0.0 10.0 1.0 relative treatment effect www.metaEvidence.org 2024-10-02 15:27 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 173
- treatments: 416,864